Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 1277, pseudogene (RNU6-1277P) is a genomic DNA sequence that originated from the gene encoding U6 small nuclear RNA (snRNA), but has lost its ability to produce a functional snRNA due to accumulated mutations. U6 snRNAs are essential components of the spliceosome, the molecular complex responsible for removing introns from pre-mRNA during the process of RNA splicing[1][3]. However, pseudogenes like RNU6-1277P are byproducts of genome evolution, typically generated by retrotransposition events involving U6 snRNA genes[7]. These sequences do not encode a functional product or participate in splicing, serve no known biological function, and are not considered therapeutic targets, receptors, or enzymes[7]. There is currently no evidence linking RNU6-1277P to drug interactions, biomarker applications, or disease states.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1277, pseudogene (RNU6-1277P).